Status:
COMPLETED
Evaluation of Aortic Stiffness as a Prognostic Indicator of Aortic Dilatation in Patients With Bicuspid Aortic Valve by Multimodal Imaging
Lead Sponsor:
French Cardiology Society
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
Centre National de la Recherche Scientifique, France
Conditions:
Bicuspid Aortic Valve
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The objective is the development and validation of morphological markers informative of aortic dilatation in order to improve the precision of the risk of aneurysm of the thoracic aorta and of acute a...
Detailed Description
Background Bicuspid Aortic Valve (BAV) is the most common congenital heart defect with prevalence around 1 to 2% of the general population . It is defined by the presence of two functional cusps with ...
Eligibility Criteria
Inclusion
- Adults over 18 years of age,
- confirmed BAV by TTE computed tomography or MRI.
- Adults benefiting from a social security scheme,
- having received information on the research
- having signed the consent form
Exclusion
- Patient with a syndromic form of BAV:
- Loeys-Dietz syndrome,
- Turner syndrome
- Williams-Beuren syndrome
- Shone syndrome
Key Trial Info
Start Date :
November 7 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 24 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03474159
Start Date
November 7 2018
End Date
September 24 2024
Last Update
February 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Européen Georges Pompidou
Paris, France, 75015